New long-term data for Novartis’ once-yearly osteoporosis jab Aclasta/Reclast have cemented its safety and efficacy profile, showing that the drug preserves bone mass and slashes the risk of new spine ...

Aclasta reduced the risk of new spine fractures by 52% over six years versus patients who stopped treatment after three years[1] New data from six-year study validate Aclasta safety profile and ...

• Single-dose therapy given once a year shown to provide significant bone protection benefits and may improve long-term treatment compliance Aclasta® (zoledronic acid 5 mg) has received the Jordan ...

Shown to be highly effective in strengthening bones and protecting against fractures in all key sites, including hip and spine[1] Once-yearly dosing provides potential for compliance benefits and long ...

Add articles to your saved list and come back to them any time. Swiss drugmaker Novartis said on Saturday that clinical tests had shown its once-yearly Aclasta medicine had proved effective in ...